Background: A randomized clinical trial was performed to clarify whether the continuous use of methimazole (MMI) during radioiodine therapy (RI 131 ) influences the final outcome of this therapy.
Results:
The 24-hour thyroid I 131 uptake was lower in the '+MMI' group (44.8 ± 15.6%) than in the '-MMI' group (62.1 ± 9.9%; p<0.001). At 3 weeks after therapy, no significant change in serum free T 4 index was observed in the '+MMI' group (109 ± 106 versus 83 ± 28 nmol/L at baseline; P = 0.26), contrasting with an increase in the '-MMI' group (180 ± 110 versus 82 ± 26 nmol/L at baseline; P<0.001). The number of cured patients was 17 (44%) and 22 (61%) in the '+MMI' and '-MMI' groups, respectively (P = 0.17). Cured patients tended to have a lower 24-hour thyroid I 131 uptake (50.1 ± 13.8% versus 56.4 ± 17.1%; P = 0.09). By adjusting for a possible interfactorial relationship through a regression analysis (variables analyzed: randomization; 24-h and 96-h thyroid uptake; type and duration of disease; age; gender; presence of thyroid antibodies; thyroid volume; dose of MMI), only the continuous use of MMI correlated with treatment failure (P = 0.006) whereas a low thyroid I 131 uptake predicted a better outcome (P = 0.006).
Conclusion:
Continuous use of methimazole hinders an excessive increase of the thyroid hormones during RI 131 therapy of hyperthyroid diseases. However, such a strategy seems to reduce the final cure rate, although this adverse effect paradoxically is attenuated by the concomitant reduction of the thyroid I 131 uptake. 
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